← All blog posts

Skyrizi (Risankizumab) for IBD: Patient Questions Beyond the Ad

Posted on August 15, 2026 · Treatment

Content note: Educational content aligned with publicly available patient materials from the Crohn's & Colitis Foundation and other major IBD education sources. Content is used under license from the Foundation for patient education; the Foundation does not endorse IBDPal or MediVue products or services. Last reviewed August 2026. Not individual medical advice.

Educational use only. IBDPal does not provide medical advice, diagnosis, or treatment. Always consult your gastroenterologist or IBD care team for personal decisions.

Skyrizi searches rose as IL-23 medicines expanded in IBD care. Ads do not answer bathroom logistics, fatigue, or infection rules. Use this as a question list for your gastroenterologist.

Themes patients bring to clinic

Risankizumab targets IL-23 pathways used in Crohn's treatment plans.

Prepare your visit

Indications and dosing evolve. Your label and clinician override any blog.

When to seek care promptly

This page cannot diagnose you. Severe bleeding, black tarry stools, fainting, fever with rapid decline, or inability to keep fluids down need urgent evaluation. See when to go to the ER and flare help.

Common myths

Questions for your gastroenterologist

Track patterns in IBDPal and bring a one-week log to visits. Related: prior auth · first 12 weeks · vaccines. Hub: stool and labs decoder.

Read the full interactive version on ibdpal.org.